Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05558722
What this trial is testing

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer Stage II
Xijing Hospital 31
Testing effectiveness (Phase 2)Study completedNCT03481998
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 104
Early research (Phase 1)Study completedNCT03471663
What this trial is testing

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 200
Early research (Phase 1)Looking for participantsNCT05187832
What this trial is testing

AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC 61
Large-scale testing (Phase 3)Looking for participantsNCT05744687
What this trial is testing

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd 374
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Not applicableLooking for participantsNCT06784921
What this trial is testing

To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.

Who this might be right for
Breast Cancer Metastatic
Zhejiang Cancer Hospital 200
Testing effectiveness (Phase 2)Study completedNCT03065621
What this trial is testing

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)

Who this might be right for
Breast Cancer Female
Jules Bordet Institute 100
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Large-scale testing (Phase 3)Active Not RecruitingNCT04546009
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 992
Early research (Phase 1)Active Not RecruitingNCT05654532
What this trial is testing

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 100
Large-scale testing (Phase 3)Study completedNCT04109066
What this trial is testing

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 521
Testing effectiveness (Phase 2)Looking for participantsNCT05898399
What this trial is testing

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Who this might be right for
Advanced Solid TumorMetastatic Solid Tumor
Artios Pharma Ltd 181
Testing effectiveness (Phase 2)Looking for participantsNCT06369285
What this trial is testing

Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc. 225
Testing effectiveness (Phase 2)Study completedNCT02025985
What this trial is testing

Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies

Who this might be right for
Ovarian CarcinomaEndometrial CarcinomaCervical Carcinoma
Karyopharm Therapeutics Inc 116
Not applicableLooking for participantsNCT06158919
What this trial is testing

PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

Who this might be right for
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
Fudan University 58
Testing effectiveness (Phase 2)Looking for participantsNCT06764940
What this trial is testing

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Who this might be right for
HER2-negative Breast Cancer Patients With Brain Metastases
Biostar Pharma, Inc. 120
Not applicableApproved For MarketingNCT02792725
What this trial is testing

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)UnknownNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Testing effectiveness (Phase 2)Looking for participantsNCT06908668
What this trial is testing

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Who this might be right for
HER2-Negative Locally Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 170
Next Page